Message from the president

Takara Bio Inc. was established in 2002 as a carve-out of Takara Shuzo Co., Ltd. (now Takara Holdings Inc.) to maximize the characteristics of the biomedical business unit, starting with Takara Shuzo's predecessor, Takara Shuzo Co., Ltd.

  Takara Bio Group is currently expanding earnings, achieving the 11th consecutive year of higher earnings, with contribution by overseas growth of its research reagent, expansion of its CDMO business, and advancement in its gene therapy project. In May 2020, Takara Bio formulated and launched our "Long-Term Management Plan FY2026" and "Medium-Term Management Plan FY2023". Based on our corporate philosophy of "Contributing to the health of humankind through the development of revolutionary biotechnologies such as gene therapy," Takara Bio aims to be a drug discovery company that continuously creates new modalities by advancing the development of bio-drug discovery platform technologies through our core businesses of "research reagents and scientific instruments businesses" and "CDMO business".
  Currently, a COVID-19 is prevalent worldwide, and the situation remains unpredictable. With all our resources, Takara Bio has developed a PCR testing kit that facilitates the detection of SARS-Cov-2, and is working to resolve social issues by cooperating in the development of vaccines for the prevention of COVID-19 under a stable production and supply system.

  Takara Bio Group will continue to create new value through proactive business activities, achieve sustainable growth, and contribute to society.

  We deeply appreciate your ongoing support.

   Koichi Nakao

return to top

Our website uses cookies to ensure that we give you the best user experience.Read more
By continuing to use our site, you consent to our cookies.